Market Cap 9.20M
Revenue (ttm) 0.00
Net Income (ttm) -15.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,100
Avg Vol 295,872
Day's Range N/A - N/A
Shares Out 2.01M
Stochastic %K 73%
Beta 1.52
Analysts Strong Sell
Price Target $19.25

Company Profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 980 4182
Address:
42127 Pleasant Forest Court, Ashburn, United States
revuelto
revuelto Jul. 1 at 3:03 AM
$QNRX if I had to call out one potential issue, it’s the topline potentially slipping to q1 2027…tight runway, cash burn will only accelerate with p3 underway…a capital raise is a near certainty. the question is whether Dr. Myers can leverage his business savvy to raise on favorable terms…he’s smart I think, let’s wait it out…for an ultra rare disease and high unmet need, it has multiple ODDs + fast track, established brand, Japan infrastructure already in place…. better positioned than most micro caps…an ounce of good news and its cap will dramatically increase.. 🐋
1 · Reply
SolomanWisdom247
SolomanWisdom247 Jun. 30 at 10:32 PM
$QNRX scam stock
1 · Reply
Zackpedia
Zackpedia Jun. 30 at 8:44 PM
$QNRX Selling time at 4.9!
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 30 at 12:32 PM
$QNRX QNRX Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
0 · Reply
kakatrade
kakatrade Jun. 26 at 3:10 PM
$QNRX we staying bullish...time to push for 5 and lets get the fomo's in...lets go!!!
0 · Reply
Zackpedia
Zackpedia Jun. 26 at 12:29 PM
$QNRX Down to 3.7! You could’ve sold when I alerted and bought back if you wanted.
0 · Reply
kakatrade
kakatrade Jun. 25 at 4:56 PM
$QNRX would be nice if we can run her harder and fill the gaps on daily...Analyst PT is minimum 2 digit, why are we dragging???
0 · Reply
MasterofThePennies
MasterofThePennies Jun. 25 at 2:26 PM
$RAIN only stock I’m in at the moment. Keeping a close eye on $QNRX here as well for a possible re-entry. Slow market and lots of red today, bears in control on a majority of pennies, this is a trade carefully or not at all day for me.
1 · Reply
kakatrade
kakatrade Jun. 25 at 2:12 PM
$QNRX bullish - entering Apex... get ready
0 · Reply
MadMaverick
MadMaverick Jun. 25 at 11:03 AM
0 · Reply
Latest News on QNRX
Quoin Pharmaceuticals initiated with a Buy at ThinkEquity

2026-06-15T10:17:58.000Z - 19 days ago

Quoin Pharmaceuticals initiated with a Buy at ThinkEquity


Quoin Pharmaceuticals submits QRX003 IND application to FDA

2026-06-02T14:36:20.000Z - 4 weeks ago

Quoin Pharmaceuticals submits QRX003 IND application to FDA


Quoin Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 9:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Earnings release: Q1 2026


Quoin Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 9:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Quarterly report: Q1 2026


Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

2026-05-04T10:11:14.000Z - 2 months ago

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital


Quoin Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Annual report: Q4 2025


Quoin Pharmaceuticals Earnings release: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Earnings release: Q4 2025


Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-03-25T13:40:52.000Z - 3 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes


Quoin Pharmaceuticals Slides: Corporate presentation

Mar 25, 2026, 7:00 AM EDT - 3 months ago

Quoin Pharmaceuticals Slides: Corporate presentation


Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-02-17T15:25:48.000Z - 4 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes


Quoin announces submission to Japanese MHLW for ODD for QRX003

2026-01-27T13:36:50.000Z - 5 months ago

Quoin announces submission to Japanese MHLW for ODD for QRX003


Quoin announces achievement of rapamycin target loadings

2025-11-11T13:35:24.000Z - 8 months ago

Quoin announces achievement of rapamycin target loadings


Quoin Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 8 months ago

Quoin Pharmaceuticals Quarterly report: Q3 2025


Quoin Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 9:30 AM EST - 8 months ago

Quoin Pharmaceuticals Earnings release: Q3 2025


Quoin Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Quoin Pharmaceuticals Quarterly report: Q2 2025


Quoin Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Quoin Pharmaceuticals Earnings release: Q2 2025


Quoin Pharmaceuticals Provides Product Portfolio Update

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Product Portfolio Update


Quoin Pharmaceuticals Proxy statement: Proxy Filing

Jul 17, 2025, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing


Quoin Pharmaceuticals Proxy statement: Proxy Filing

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing


Quoin Pharmaceuticals Slides: Corporate Presentation

Jun 13, 2025, 4:27 PM EDT - 1 year ago

Quoin Pharmaceuticals Slides: Corporate Presentation


Quoin Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Earnings release: Q1 2025


Quoin Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q1 2025


Quoin Pharmaceuticals Slides: Corporate Presentation

Dec 16, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Slides: Corporate Presentation


Quoin Pharmaceuticals Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q3 2024


Quoin Pharmaceuticals Earnings release: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Earnings release: Q3 2024


Quoin Pharmaceuticals Proxy statement: Proxy Filing

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing


Quoin Pharmaceuticals Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing


Quoin Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Quarterly report: Q2 2024


Quoin Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q2 2024


Quoin Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Quarterly report: Q1 2024


Quoin Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q1 2024


Quoin Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing


Quoin Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings Call Transcript: Q4 2023


Quoin Pharmaceuticals Annual report: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Annual report: Q4 2023


Quoin Pharmaceuticals Earnings release: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q4 2023


Quoin Pharmaceuticals Annual report: Q4 2024

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Annual report: Q4 2024


Quoin Pharmaceuticals Earnings release: Q4 2024

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q4 2024


revuelto
revuelto Jul. 1 at 3:03 AM
$QNRX if I had to call out one potential issue, it’s the topline potentially slipping to q1 2027…tight runway, cash burn will only accelerate with p3 underway…a capital raise is a near certainty. the question is whether Dr. Myers can leverage his business savvy to raise on favorable terms…he’s smart I think, let’s wait it out…for an ultra rare disease and high unmet need, it has multiple ODDs + fast track, established brand, Japan infrastructure already in place…. better positioned than most micro caps…an ounce of good news and its cap will dramatically increase.. 🐋
1 · Reply
SolomanWisdom247
SolomanWisdom247 Jun. 30 at 10:32 PM
$QNRX scam stock
1 · Reply
Zackpedia
Zackpedia Jun. 30 at 8:44 PM
$QNRX Selling time at 4.9!
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 30 at 12:32 PM
$QNRX QNRX Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
0 · Reply
kakatrade
kakatrade Jun. 26 at 3:10 PM
$QNRX we staying bullish...time to push for 5 and lets get the fomo's in...lets go!!!
0 · Reply
Zackpedia
Zackpedia Jun. 26 at 12:29 PM
$QNRX Down to 3.7! You could’ve sold when I alerted and bought back if you wanted.
0 · Reply
kakatrade
kakatrade Jun. 25 at 4:56 PM
$QNRX would be nice if we can run her harder and fill the gaps on daily...Analyst PT is minimum 2 digit, why are we dragging???
0 · Reply
MasterofThePennies
MasterofThePennies Jun. 25 at 2:26 PM
$RAIN only stock I’m in at the moment. Keeping a close eye on $QNRX here as well for a possible re-entry. Slow market and lots of red today, bears in control on a majority of pennies, this is a trade carefully or not at all day for me.
1 · Reply
kakatrade
kakatrade Jun. 25 at 2:12 PM
$QNRX bullish - entering Apex... get ready
0 · Reply
MadMaverick
MadMaverick Jun. 25 at 11:03 AM
0 · Reply
kakatrade
kakatrade Jun. 25 at 10:03 AM
$QNRX Anybody ready to pump this to hit the scanner for the shopper...this gapped down from 3.7, looks like a good reversal run
0 · Reply
MrPlastic
MrPlastic Jun. 25 at 8:31 AM
$QNRX 3. Near-term dated catalyst with an upside-funded structure. Comprehensive Phase 2/investigator data is guided for the coming months, Phase 3 prepped to enroll right after. And the PIPE is structured so the milestone warrants (~$88M, fixed strikes) arm on clinical success — good data funds the company forward instead of forcing a raise. The honest risks (because if I don't say them I'm just pumping): it's a binary — bad data and this drops hard. The warrant strikes sit above the current price, so the data has to be good and move the stock for that funding mechanism to kick in; a timeline slip raises real financing pressure. Size accordingly. But a dated near-term binary, in a disease with no competition, with the regulatory and commercial groundwork already laid and a funding path on the upside — that's a cleaner setup than most pre-data microcaps. That's why I'm long. Anyone else actually doing DD here — What's your read on the Phase 2 endpoints / the funding bridge?
0 · Reply
MrPlastic
MrPlastic Jun. 25 at 8:31 AM
$QNRX 2. Zero approved treatments = a lower efficacy bar than people think. Netherton has no FDA-approved therapy. The FDA judges against existing care, and existing care is nothing. So this isn't "cure or bust" — meaningful, consistent improvement over nothing can clear the bar. The compassionate-use signals back this: a 6-month-old went from emollient every 2 hours 24/7 to almost none in 3 weeks, with neutrophil levels (objective infection-risk marker) normalizing. The 15-month patient: full skin clearing, zero itch, sustained. Small/open-label — but the FDA's flexibility (single Phase 3, randomized-withdrawal design, all the designations) tells you they see something real....
0 · Reply
MrPlastic
MrPlastic Jun. 25 at 8:29 AM
$QNRX Why I'm long QNRX — actual reasons, not hype. Done a lot of DD on this one. Sharing the 3 real bull case for anyone evaluating it seriously: 1. The regulatory package is way ahead of the market cap. QRX003 has Orphan Drug Designation in the US, EU, and Japan, plus US Fast Track and Rare Pediatric Disease. That last one is key — approval could trigger a Priority Review Voucher worth ~$150-200M in non-dilutive cash (program reauthorized through 2029). Five designations, three territories, US/EU/Japan commercial subsidiaries already built — for a company trading near $10M. That's a lot of pathway de-risking already done.....
0 · Reply
MadMaverick
MadMaverick Jun. 25 at 4:52 AM
⚡WATCHLIST RECAP⚡ ✅ $PLSM | +14.78% max profit ✅ $FRTT | +26.45% max profit ✅ $QNRX | +18.57% max profit ✅ $VTAK | +29.56% max profit - $PLSM: With an entry above $11.30, the stock reached a daily high of $12.97, yielding a maximum profit of approximately 14.78%. - $FRTT: With an entry above $3.10, the stock reached a daily high of $3.92, yielding a maximum profit of approximately 26.45%. - $QNRX: With an entry above $4.20, the stock reached a daily high of $4.98, yielding a maximum profit of approximately 18.57%. - $VTAK: With an entry above $1.43, the stock reached a daily high of $1.79, yielding a maximum profit of approximately 29.56%.
0 · Reply
Zackpedia
Zackpedia Jun. 25 at 12:14 AM
$QNRX Down to 3.5 now, you could’ve sold when I alerted…
1 · Reply
Zackpedia
Zackpedia Jun. 24 at 11:55 PM
$QNRX 3.8!
0 · Reply
Profitrip
Profitrip Jun. 24 at 10:16 PM
$QNRX on AH Scan / low float / rvol over 7
0 · Reply
revuelto
revuelto Jun. 24 at 7:57 PM
$QNRX when does the celebration rally begin, today or tomorrow? 🎉
0 · Reply
Zackpedia
Zackpedia Jun. 24 at 4:15 PM
$QNRX 3.4 support
0 · Reply
Kevin73ca
Kevin73ca Jun. 24 at 3:22 PM
$QNRX this is getting uploaded fir a very big jump only patience needed Moments this will go way fast once it starts
0 · Reply
artuskis
artuskis Jun. 24 at 3:04 PM
$QNRX I don't even know with this one, company seems to be favourable with analysts but that's a long term assumption, either the company dying or today provided a good long term entry, too hard to figure out which one it is... Hopefully not another $DEVS
0 · Reply